How to know when a re-biopsy is necessary for an advanced NSCLC patient?

Speaker: Solange Peters

In non-squamous advanced NSCLC, 5 biomarkers should be tested in the initial biopsy to base the first line treatment decision: EGFR, ALK, ROS-1, BRAF and PD-L1.
When not carried out at baseline, it is still important to search for these biomarkers to make a treatment decision after progression.
When an initial biopsy results are available, at progression it is not mandatory to re-test.
However, in case more targeted therapies are available at the clinic or for clinical research purposes if rare mutations are found, the second biopsy may give valuable information to decide on a second or third line treatment, especially when an oncogenic driver has been identified at baseline.

In this educational video of the 'How To' series, Solange Peters explains how to know when a re-biopsy is necessary for an advanced NSCLC patient.